Endocrine Abstracts

Background and aims: Endocrine osteoporosis should be uncommon in contemporary times due to improved early diagnosis of endocrinopathies. Our objective is to analyze the osteodensitometric profiles of patients under endocrinopathy care.

Methods: A cross-sectional study of patients followed for endocrinopathies at the Endocrinology Department of the Hassan II University Hospital of Fez, spanning from the beginning of January 2016 to January 2022. Exclusion criteria encompassed patients receiving treatment for inflammatory rheumatism and those under care for systemic diseases. Analysis was conducted using SPSS26 software.

Results: A total of 83 patients diagnosed with endocrinopathy underwent Bone Mineral Density (BMD) assessment. The average age was 35.77 years, and a majority were female (73.49%). Primary and secondary amenorrhea were the predominant reasons for consultation, accounting for 37.35% of cases. 15.66% of the cases exhibited normal osteodensitometry, while 84.34% displayed abnormal Bone Mineral Density (BMD), with 34.94% diagnosed with osteoporosis and 49.40% with osteopenia. The identification of BMD issues, primarily osteoporosis and osteopenia, occurred in 87.14% of cases subsequent to the detection of the endocrinopathy. Hypogonadism prevailed among endocrinopathies, accounting for 71.08% of cases. Hyperparathyroidism constituted 19.28%, endogenous hypercorticism at 6.02%, and acromegaly at 3.62%. Osteoporosis was more commonly observed in the spine, occurring in 26.3% of cases with an average T-score of -2.88±0.85. In the femur, osteopenia was present in 25.6%, while osteoporosis was noted in 8.64%, with a mean T-score of -1.46±1.02. All patients underwent treatment for the underlying cause of their endocrinopathy along with adopting hygienic-dietary measures. Anti-osteoporotic treatment, primarily bisphosphonates, was prescribed in 34.94%. Regarding the follow-up, only 34.94% managed to undergo a follow-up Bone Mineral Density (BMD) assessment, and in every instance, there was an enhancement observed in T-scores.

Conclusions: This study underscores the notable occurrence of osteoporosis and osteopenia among patients undergoing treatment for endocrine disorders. Consequently, it emphasizes the necessity to systematically assess bone health in any endocrinopathy that may lead to rheumatological complications. Additionally, it highlights the importance of a thorough etiological investigation, aiming to identify an underlying endocrine pathology before the onset of osteoporosis or osteopenia.